Results 41 to 50 of about 1,282 (161)

Lyme disease and the pursuit of a clinical cure

Frontiers in Medicine, 2023
Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the United States. Many aspects of the disease are still topics of controversy within the scientific and medical communities.
Heather Adkison, Monica E. Embers
doaj   +1 more source

Equal-opportunity treatment of EBV-PTLD [PDF]

Blood, 2012
In 1994, investigators at the Memorial Sloan-Kettering Cancer Center described the first successful use of donor lymphocyte infusion (DLI) to treat Epstein-Barr virus (EBV) after transplantation lymphoproliferative disorder (PTLD) after hemopoietic stem cell transplantation (HSCT).
openaire   +2 more sources

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

Transplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam, Abdinoor Abdi, Wyatt Tarter, Ben Langworthy, Adam Bregman, Karam M. Obeid   +5 more
wiley   +1 more source

Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET

Journal of Neuroinflammation, 2018
The pathophysiology of post-treatment Lyme disease syndrome (PTLDS) may be linked to overactive immunity including aberrant activity of the brain’s resident immune cells, microglia.
Jennifer M. Coughlin, Ting Yang, Alison W. Rebman, Kathleen T. Bechtold, Yong Du, William B. Mathews, Wojciech G. Lesniak, Erica A. Mihm, Sarah M. Frey, Erica S. Marshall, Hailey B. Rosenthal, Tristan A. Reekie, Michael Kassiou, Robert F. Dannals, Mark J. Soloski, John N. Aucott, Martin G. Pomper   +16 more
doaj   +1 more source

Multidisciplinary Management of Suspected Lyme Borreliosis: Clinical Features of 569 Patients, and Factors Associated with Recovery at 3 and 12 Months, a Prospective Cohort Study

Microorganisms, 2022
Introduction. Because patients with a suspicion of Lyme borreliosis (LB) may have experienced difficult care paths, the Tick-Borne Diseases Reference Center (TBD-RC) was started in 2017.
Alice Raffetin, Julien Schemoul, Amal Chahour, Steve Nguala, Pauline Caraux-Paz, Giulia Paoletti, Anna Belkacem, Fernanda Medina, Catherine Fabre, Sébastien Gallien, Nicolas Vignier, Yoann Madec, on the behalf of the Tick-Borne Diseases Reference Center-Paris and Northern Region Working Group   +12 more
doaj   +1 more source

A Case of Intermittent Fever a Decade After Renal Transplantation

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Disseminated histoplasmosis is a potentially serious complication after organ transplantation; however, its occurrence is rare, even in endemic regions. Diagnosis can be challenging, particularly in patients with nonspecific symptoms such as intermittent fever or lethargy.
Merazul Islam Ony, Baris Afsar, Bahar Bastani   +2 more
wiley   +1 more source

Complement Evasion in Borrelia spirochetes: Mechanisms and Opportunities for Intervention

Antibiotics, 2019
Lyme disease (LD) is an increasingly prevalent, climate change-accelerated, vector-borne infectious disease with significant morbidity and cost in a proportion of patients who experience ongoing symptoms after antibiotic treatment, a condition known as ...
Jonathan W. Locke
doaj   +1 more source

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder

Leukemia Research Reports, 2023
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML).
Süreyya Yiğit Kaya, Abdullah Emre Askin, Sebnem Bektas, Aslı Çakır, Ömür Gökmen Sevindik   +4 more
doaj   +1 more source

A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes

Diabetic Medicine, Volume 43, Issue 3, March 2026.
Abstract Aims To explore UK key‐opinion leader perspectives on the future role of stem cell‐derived islets (sc‐islets) in islet transplantation for people with type 1 diabetes (T1D). Methods Four UK‐based key‐opinion leaders evaluated current limitations of donor islet transplantation and reviewed emerging evidence, clinical pathways and logistical ...
Thomas Strakosch, Shareen Forbes
wiley   +1 more source

What to Do When Medical Evidence Can Only Be Generated Through Routine Data: An Example From Pediatric Oncology

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Children undergoing allogeneic stem cell transplantation often receive off‐label rituximab treatment for Epstein–Barr virus reactivation, using adult dosing without pediatric evidence. This project aims to develop a clinical decision support tool (CDSS) that provides evidence‐based dosing scenarios by analyzing real‐world patient data.
Birgit Burkhardt, Antje Walz, Dietrich Knoerzer   +2 more
wiley   +1 more source